🇺🇸 FDA
Patent

US 11878977

JAK inhibitors containing a 4-membered heterocyclic amide

granted A61KA61K31/437A61P

Quick answer

US patent 11878977 (JAK inhibitors containing a 4-membered heterocyclic amide) held by Theravance Biopharma R&D IP, LLC expires Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Jan 23 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 18 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/437, A61P, A61P11/00, A61P11/06